
Vaxcyte, Inc. (PCVX)
Last updated: 2026-10-22 12:06:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Vaxcyte, Inc. (PCVX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $62.59, with a market capitalization of $10.42B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $39.87 to $90.75. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$10.42B | |
$63.21 | |
$121.06 | |
$15.51 | |
$63.23 | |
183.00 | |
1.97M | |
-- | |
$90.75 | |
$39.87 | |
-- | |
2001-12-30 |
Vaxcyte, Inc. (PCVX) Pre-Market Stock Price
Vaxcyte, Inc. (PCVX) is trading at $62.59 in pre-market trading as of 2026-10-22 11:29:00, down 1.02% ($0.64) from the previous close of $63.23
Pre-market trading shows how investors are pricing PCVX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Vaxcyte, Inc. (PCVX) 7-Day Stock Price Change
Over the past seven days, Vaxcyte, Inc. (PCVX) moved from $66.80 to $62.59, representing a decline of 6.31% ($4.21).
The stock traded between $62.37 and $71.09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.52 million shares, down versus the previous seven-day period, indicating lower trading activity.
PCVX 52-Week Price Position
Position in Range: 44.6%
PCVX is currently trading at $62.59, placing it 44.6% of the way from its 52-week low of $39.87 to its 52-week high of $90.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Vaxcyte, Inc. (PCVX)?
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Vaxcyte, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 507 |
| CEO | Grant E. Pickering |
| Founded | 2013 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Vaxcyte, Inc. (PCVX) Stock on MEXC
Eligible investors can buy real shares of Vaxcyte, Inc. (PCVX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Vaxcyte, Inc. (PCVX) stock price today?
2.Is PCVX stock going up or down today?
3.What is PCVX pre-market price?
4.What is PCVX after-hours price?
5.Is PCVX stock trading now?
6.Where does PCVX sit relative to its 52-week high and low?
7.What sector is Vaxcyte, Inc. in?
8.What is Vaxcyte, Inc.'s market capitalization and where is it listed?
9.How is PCVX valued in terms of P/E ratio and EPS?
10.Does Vaxcyte, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
PCVX Stock Calculator
Estimate the value between PCVX shares and USD.
PCVX Shares to USD
1.00 PCVX shares = 62.585 USD
Calculations are estimates based on the latest available price and are for reference only.


